Medically reviewed by Christopher Lee, MD Treatment for ATTR-CM has historically been symptom management. However, until 2019, the United States Food and Drug Administration (FDA) did not approve any ...

In this video, Shahzad Raza, MD, discusses safety and efficacy data from Nexicart-2, which studied the use of chimeric antigen receptor T-cell therapy in relapsed or refractory light chain amyloidosis ...

In this video, Shahzad Raza, MD, discusses teclistamab as a potential treatment for patients with relapsed or refractory systemic light chain amyloidosis.“Teclistamab has already been approved in ...

There is decreased risk of all-cause and CV mortality in patients with transthyretin amyloidosis with cardiomyopathy treated with vutrisiran.

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of ...

The AI model effectively spotted all subtypes of amyloidosis in the dataset, with an area under the receiver-operating characteristic curve (AUROC) of 0.93, a sensitivity of 85% for identifying ...

Anselamimab is an anti-fibril monoclonal antibody designed to reduce or eliminate amyloid deposits by binding with targets of amino acids on misfolded amyloid fibrils.

An artificial intelligence model developed by Mayo Clinic and Ultromics accurately screens for cardiac amyloidosis using a ...

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an ...

An experimental AstraZeneca (NASDAQ:AZN) drug, anselamimab, failed to extend survival or cut heart-related hospitalizations in patients with a rare plasma cell disorder, disappointing hopes it could ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...